These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 32233603)

  • 21. Prognostic Value of Peripheral Blood Lymphocyte Telomere Length in Gynecologic Malignant Tumors.
    Shanta K; Nakayama K; Ishikawa M; Ishibashi T; Yamashita H; Sato S; Sasamori H; Sawada K; Kurose S; Mahmud HM; Razia S; Iida K; Ishikawa N; Kyo S
    Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32512904
    [No Abstract]   [Full Text] [Related]  

  • 22. [Relationships between decreased LAMC3 and poor prognosis in ovarian cancer].
    Lei SM; Liu X; Xia LP; Ke Y; Wei LW; Li L; Yin FJ
    Zhonghua Fu Chan Ke Za Zhi; 2021 Jul; 56(7):489-497. PubMed ID: 34304441
    [No Abstract]   [Full Text] [Related]  

  • 23. miR-944 acts as a prognostic marker and promotes the tumor progression in endometrial cancer.
    He Z; Xu H; Meng Y; Kuang Y
    Biomed Pharmacother; 2017 Apr; 88():902-910. PubMed ID: 28178620
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Integrated bioinformatics analysis for the screening of hub genes and therapeutic drugs in ovarian cancer.
    Yang D; He Y; Wu B; Deng Y; Wang N; Li M; Liu Y
    J Ovarian Res; 2020 Jan; 13(1):10. PubMed ID: 31987036
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased Expression of
    Zou R; Xu H; Li F; Wang S; Zhu L
    DNA Cell Biol; 2021 Jan; 40(1):36-60. PubMed ID: 33180631
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of human epididymis protein 4 as a biomarker in gynecologic malignancies.
    Plotti F; Scaletta G; Terranova C; Montera R; De Cicco Nardone C; Luvero D; Rossini G; Gatti A; Schirò T; Moncelli M; Guzzo F; Angioli R
    Minerva Ginecol; 2019 Feb; 71(1):36-43. PubMed ID: 30318876
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bioinformatic analysis reveals MIR502 as a potential tumour suppressor in ovarian cancer.
    Li Y; Wang Q; Ning N; Tang F; Wang Y
    J Ovarian Res; 2020 Jul; 13(1):77. PubMed ID: 32660514
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnostic and prognostic role of TFF3, Romo-1, NF-кB and SFRP4 as biomarkers for endometrial and ovarian cancers: a prospective observational translational study.
    Turan H; Vitale SG; Kahramanoglu I; Della Corte L; Giampaolino P; Azemi A; Durmus S; Sal V; Tokgozoglu N; Bese T; Arvas M; Demirkiran F; Gelisgen R; Ilvan S; Uzun H
    Arch Gynecol Obstet; 2022 Dec; 306(6):2105-2114. PubMed ID: 35461390
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Endometrial Cancer: Comparison of Patients with Synchronous Primary Carcinoma of the Endometrium and Ovary vs. Endometrial Carcinoma with Ovarian Metastases.
    Juhasz-Böss I; Fehm T; Becker S; Rothmund R; Krämer B; Staebler A; Wallwiener D; Solomayer EF
    Geburtshilfe Frauenheilkd; 2012 Aug; 72(8):721-726. PubMed ID: 25258464
    [No Abstract]   [Full Text] [Related]  

  • 30. Synchronous ovarian and endometrial cancer--an international multicenter case-control study.
    Heitz F; Amant F; Fotopoulou C; Battista MJ; Wimberger P; Traut A; Fisseler-Eckhoff A; Harter P; Vandenput I; Sehouli J; Schmidt M; Kimmig R; du Bois R; du Bois A
    Int J Gynecol Cancer; 2014 Jan; 24(1):54-60. PubMed ID: 24300466
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8).
    Emons G; Kurzeder C; Schmalfeldt B; Neuser P; de Gregorio N; Pfisterer J; Park-Simon TW; Mahner S; Schröder W; Lück HJ; Heubner ML; Hanker L; Thiel F; Hilpert F
    Gynecol Oncol; 2016 Mar; 140(3):450-6. PubMed ID: 26731724
    [TBL] [Abstract][Full Text] [Related]  

  • 32. RIPK4 Is an Immune Regulating-Associated Biomarker for Ovarian Cancer and Possesses Generalization Value in Pan-Cancer.
    Liao C; Zhao YX; Han WD; Lai NY
    J Immunol Res; 2022; 2022():7599098. PubMed ID: 35310605
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Upregulation of KIF26B, Cell Migration and Proliferation of Human Ovarian Cancer Cell Lines In Vitro, and Patient Outcomes from Human Bioinformatic Analysis.
    Yang X; Zhang L; Xie L
    Med Sci Monit; 2018 Jun; 24():3863-3872. PubMed ID: 29880787
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term quality of life and sexual function of elderly people with endometrial or ovarian cancer.
    Mamguem Kamga A; Bengrine-Lefevre L; Quipourt V; Favier L; Darut-Jouve A; Marilier S; Arveux P; Desmoulins I; Dabakuyo-Yonli TS
    Health Qual Life Outcomes; 2021 Feb; 19(1):56. PubMed ID: 33579310
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic factors and genes associated with endometrial cancer based on gene expression profiling by bioinformatics analysis.
    Zhang Y; Zhang W; Li X; Li D; Zhang X; Yin Y; Deng X; Sheng X
    Arch Gynecol Obstet; 2016 Jun; 293(6):1287-95. PubMed ID: 26437953
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of Differentially Expressed Genes (DEGs) Relevant to Prognosis of Ovarian Cancer by Use of Integrated Bioinformatics Analysis and Validation by Immunohistochemistry Assay.
    Zhang L; Sun L; Zhang B; Chen L
    Med Sci Monit; 2019 Dec; 25():9902-9912. PubMed ID: 31871312
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic Role of microRNA-205 in Human Gynecological Cancer: A Meta-Analysis of Fourteen Studies.
    Wu Z; Tang H; Xiong Q; Liu D; Xia T; Liang H; Ye Q
    DNA Cell Biol; 2020 May; 39(5):875-889. PubMed ID: 32354230
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The gynecological surveillance of women with Lynch syndrome in Sweden.
    Tzortzatos G; Andersson E; Soller M; Askmalm MS; Zagoras T; Georgii-Hemming P; Lindblom A; Tham E; Mints M
    Gynecol Oncol; 2015 Sep; 138(3):717-22. PubMed ID: 26177554
    [TBL] [Abstract][Full Text] [Related]  

  • 39. LINC-PINT suppresses tumour cell proliferation, migration and invasion through targeting miR-374a-5p in ovarian cancer.
    Hao T; Huang S; Han F
    Cell Biochem Funct; 2020 Dec; 38(8):1089-1099. PubMed ID: 32638404
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exploiting systems biology to investigate the gene modules and drugs in ovarian cancer: A hypothesis based on the weighted gene co-expression network analysis.
    Nomiri S; Karami H; Baradaran B; Javadrashid D; Derakhshani A; Nourbakhsh NS; Shadbad MA; Solimando AG; Tabrizi NJ; Brunetti O; Nasseri S; Racanelli V; Safarpour H; Silvestris N
    Biomed Pharmacother; 2022 Feb; 146():112537. PubMed ID: 34922114
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.